Brief: Cantargia Presents New Preclinical Data On Nadunolimab

Cantargia AB

20/09/2023 11:04

Sept 20 (Reuters) - Cantargia AB  CANTA.ST :
    * NEW PRECLINICAL DATA ON NADUNOLIMAB POTENTIAL TO ENHANCE
ANTI-TUMOR EFFECT OF IMMUNOTHERAPY PRESENTED AT CRI-ENCI-AACR
    * DATA SHOW THAT NADUNOLIMAB REDUCES IMMUNE SUPPRESSION AND
IMPROVES ANTI-TUMOR EFFECT OF A CANCER VACCINE

Source text for Eikon:  ID:nMFN24N5JZ 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))